{
  "docId": "019de075-12bd-74a7-bc75-4587e4948a57",
  "docSlug": "9c54f748d4238e6a3a690a4101a45e99",
  "documentTitle": "Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 50,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "key_messages",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "The slide uses a Y-shaped antibody diagram to annotate specific functional improvements.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-12bd-74a7-bc75-4587e4948a57/17",
  "deckHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57",
  "deckJsonHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57.json",
  "deckAnchorHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.0017,
        "y": 0.0028
      },
      "kind": "image",
      "text": "Antibody diagram",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e8191e20-fad1-43cb-acfe-2a23dd4dc0d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.52,
        "y": 0.6
      },
      "kind": "list",
      "text": "Significantly extended half-life: Q8-Q12W dosing based on validated half-life extension technology",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "202c9d4d-28b4-4a4e-b619-6c33c386a789",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.02,
        "y": 0.28
      },
      "kind": "list",
      "text": "Epitope maintained: Validated pharmacology, Equivalent potency",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8e93004c-6c35-48f9-9445-f159f1722563",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.52,
        "y": 0.3
      },
      "kind": "list",
      "text": "Potential for IP into 2040s: Diverse coverage of lead and backup series",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b3f1ed16-d390-442c-972d-cc9eeff76a99",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.02,
        "y": 0.6
      },
      "kind": "list",
      "text": "High concentration SC: Ability to formulate at >150 mg/mL with low viscosity, Citrate-free formulation may improve patient comfort",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "facaabdf-097d-4706-a767-efe3cf94b903",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.13,
        "y": 0.0018
      },
      "kind": "paragraph",
      "text": "Spyre mAbs introduce significant improvements over 1st generation mAbs",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bffef662-b0d2-47ae-b747-89776af47d01",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.7,
        "y": 0.0035
      },
      "kind": "table",
      "text": "SPY001 target profile: Efficacy ≥ vedolizumab, Citrate-free subcutaneous 300 mg dose, Q8W or Q12W dosing interval",
      "attrs": null,
      "subkind": "kpi",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59106ebd-05ea-45c5-b82e-50717ebe2be5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "SPY001 exploits validated α4β7 biology with modifications designed for best-in-class properties",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7a6b7f47-6d03-4dec-9552-e7376bab7514",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "e8d0b3c4-8a2f-4a74-94e4-ae96815e0d68",
      "evidence": "list/bullet: High concentration SC: Ability to formulate at >150 mg/mL with low viscosity, Citrate-free formulation may improve patient comfort",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}